Price
$5.65-68.06%Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $5.65
- Off 52w high
- -62.0%
- 200-day average
- $8.78
- vs 200-day
- -35.6%
Revenue
$37.71MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Donn Casale
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 203
- Beta
- 0.88
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.19
Financials
Revenue
$37.71M+1685.5%Net Income
$-35.59MEBITDA
$-32.62MFree Cash Flow
$-33.71MEPS (diluted)
$-0.36Shares Outstanding (diluted)
99.69M+201.5%Operating Expenses
$61.78MCash & Debt
$138.35MRevenue by Segment (annual)
$72.19MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $84.28M | $-171.30M | $-1.74 |
| 2024 | $89.15M | $8.00M | $0.08 |
| 2023 | $30.0K | $-54.37M | $-0.57 |
| 2022 | $1.32M | $-34.68M | $-0.87 |
| 2021 | $5.51M | $-20.24M | $-0.70 |
| 2020 | $17.84M | $-1.06M | $-0.03 |
| 2019 | $0.00 | $-23.97M | $-0.72 |
| 2018 | $0.00 | $-17.58M | $-0.53 |
Valuation
SPRYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (17)
- Newsseekingalpha.com·4d ago·Positive
…ing leverage need proof. Neffy demand rose 42%, but U.S. net product revenue grew just 7%; targeted-account share reached 9%, while gross-to-net remained around 50%. SPRY cut quarterly SG&A to $43.5 million and reaffirmed year-end 2027 cash flow breakeven, but liquidity fell to $138.4 million.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair…
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
ARS Pharmaceuticals Q3 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Management pivots to a leaner, targeted prescriber approach, aiming for late-2027 cash-flow breakeven while addressing heav
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ARS Pharmaceuticals, Inc., (“ARS” or the "Company") (NASDAQ: SPRY) investors of a class action on behalf of investors that bought securities between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”).
View source ↗ - Newsgurufocus.com·77d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, S
View source ↗ - Newsgurufocus.com·81d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, S
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.
View source ↗ - Newsseekingalpha.com·96d ago·Neutral
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy ARS Pharmaceuticals has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. SPRY's Q2/2026 report highlights the new CEO's plans to reinvigorate its FDA-approved no-needle epinephrine product, neffy. The company's high-risk profile remains evident, but the high-reward potential is now the more compelling of the two.
View source ↗ - Newsgurufocus.com·98d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, A
View source ↗ - Newsseekingalpha.com·100d ago·Positive
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·100d ago·Positive
ARS Pharmaceuticals Q2 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected path to cash-flow breakeven by the end of 2027.
View source ↗ - Newszacks.com·101d ago·Negative
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.46 per share a year ago.
View source ↗ - Newsnewsfilecorp.com·101d ago·Positive
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Philadelphia, Pennsylvania--(Newsfile Corp. - August 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). What is The Investigation About?
View source ↗ - Newsbusinesswire.com·104d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY LOS ANGELES--(BUSINESS WIRE)---- $SPRY--ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY.
View source ↗ - Newsgurufocus.com·104d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY PR Newswir
View source ↗ - Newsbusinesswire.com·106d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.32 per share
Typical surprise -15.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.36 vs $-0.30miss
- Thu, Aug 13$-0.63 vs $-0.48miss
- Fri, May 15$-0.61 vs $-0.53miss
- Mon, Mar 9$-0.42 vs $-0.42beat
- Mon, Nov 10$-0.52 vs $-0.45miss
- Wed, Aug 13$-0.46 vs $-0.41miss
Estimates and results for SPRY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SPRY officers and directors.
- Bought
- —
- Sold
- $17.2m
0 trades
21 trades
- Karas Ericsold
- Fitzpatrick Alexander Asold
- Dorsey Briansold
- Chakma Justinsold
- Chakma Justinsold
- Lowenthal Richard Esold
- Scott Kathleen D.sold
- Tanimoto Sarinasold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SPRY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
